Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $41 | $22 | $33 | $46 |
| Short-Term Investments | $0 | $80 | $65 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $2 | $3 | $2 |
| Total Curr. Assets | $43 | $105 | $101 | $48 |
| Property Plant & Equip (Net) | $21 | $35 | $4 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2 | $1 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $5 | $1 |
| Total NC Assets | $23 | $38 | $9 | $7 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $66 | $143 | $110 | $55 |
| Liabilities | – | – | – | – |
| Payables | $1 | $3 | $3 | $3 |
| Short-Term Debt | $4 | $5 | $4 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $2 | $1 | $10 |
| Other Curr. Liab. | $7 | $9 | $7 | $4 |
| Total Curr. Liab. | $13 | $20 | $14 | $18 |
| LT Debt | $30 | $21 | $1 | $0 |
| Deferred Rev, NC | $12 | $12 | $14 | $2 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $42 | $34 | $15 | $2 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $34 | $27 | $4 | $1 |
| Total Liabilities | $55 | $53 | $29 | $21 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$405 | -$311 | -$249 | -$193 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $416 | $401 | $329 | $228 |
| Total Equity | $12 | $89 | $81 | $34 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $66 | $143 | $110 | $55 |
| Net Debt | -$6 | $5 | -$28 | -$44 |